The effect of low-dose sublingual minoxidil and oral dutasteride in transgender and gender-diverse individuals assigned female at birth with androgenic alopecia while on testosterone.

The University of Melbourne0 个研究点目标入组 46 人开始时间: 2023年4月6日最近更新: 2024年6月24日

适应症

试验速览

暂无简介。

•·Adults assigned female at birth, and over 18 years of age
•·Currently on standard dose of testosterone therapy
•·Experiencing scalp hair loss likely to be androgenic alopecia
•·Willing and able to attend all study visits at week 0, 6, 12, 18 and 24 and comply with treatment plan and required study procedures
•·Able to comply with the titration schedule of dispensed medications
•·Willing to have temporary 1mm tattoos on their scalp

•·Known pre-existing hair diseases, pre-existing conditions that are poorly managed and can influence or interfere with hair growth/appearance (e.g., thyroid disorders, psoriasis, eczema, seborrhoeic dermatitis) as deemed appropriate by the investigators
•·Previous treatments for hair loss e.g., finasteride/dutasteride, spironolactone, flutamide, bicalutamide, cyproterone acetate, topical or oral minoxidil within 12 weeks prior to treatment visit 1
•·Use of scalp hair growth products (e.g. ketoconazole shampoo, topical prostaglandin or prostanoid treatment, aminexil, nioxin, Fusion Hair 101, platelet rich plasma injections, low-level LED light treatment) during the study or within 6 weeks prior to treatment visit 1
•·History of hair restoration surgery
•·Current use of occlusive wig, hair extensions, or hair weaves that might interfere with assessment of response.
•·Unwilling to comply with all study procedures and assessments
•·Pregnant, planning a pregnancy or nursing a child.
•·Absolute and relative contraindications to minoxidil:
•a.Known hypersensitivity to the drug or its components (e.g. propylene glycol),
•b.Phaeochromocytoma
•c.Pregnant or breastfeeding
•d.Known history of cerebrovascular disease
•e.Pre-existing pulmonary hypertension
•f.Chronic congestive heart failure

发起方